For those of us who have been in the field for decades, this cycle of exhilaration or despair is common and manageable, but recent months have raised even further uncertainty about how progress in ...

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of ...

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer ...

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.

In a first-of-its-kind procedure, Ruben Olivares, MD, urologist at Cleveland Clinic, supported a robotic-assisted focal therapy for prostate cancer happening in Abu Dhabi from the US. The procedure ...